Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03426631 · ClinicalTrials.gov registry record · Phase 1

DAW1033B2 in Obstructive Sleep Apnea

A Phase 1 study of Obstructive Sleep Apnea (OSA), sponsored by Brigham and Women's Hospital.

Completed
Registry status
Phase 1
Development phase
13
Enrollment target
1
Study location

NCT03426631 is a Phase 1 study of Obstructive Sleep Apnea (OSA) that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 13 participants, below the 591-participant average among 12 other Obstructive Sleep Apnea (OSA) trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03426631, a Phase 1 study of Obstructive Sleep Apnea (OSA), has completed, sponsored by Brigham and Women's Hospital.

COMPLETED
Registry status
Phase 1
Development phase
13 participants
Enrollment target
1
Study location

Study Summary

Obstructive sleep apnea (OSA) is common and has major health implications but treatment options are limited. OSA patients show a marked reduction in upper airway (UA) dilator muscle activity at sleep onset and this phenomenon leads to increased collapsibility of UA compared to normal subjects. In this protocol the investigators will test the effect of DAW1033B2 administered before sleep on OSA phenotype traits and OSA severity during sleep.

Interventions

  • DRUG Placebo oral capsule
  • DRUG DAW1033B2 oral capsule

Study Locations (1)

Massachusetts

  • Sleep Disorders Research Program Brigham and Women's Hospital - Boston

Trial Details

FieldValue
Enrollment Target 13 participants
Start Date 2017-09-15
Est. Completion 2020-01-20
Phase Phase 1

Sponsor

Brigham and Women's Hospital

937 total trials

What the Registry Record Tells You About NCT03426631

The ClinicalTrials.gov registry entry for NCT03426631 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 591-participant average among 12 other Obstructive Sleep Apnea (OSA) trials with a reported enrollment target (98% lower). The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Obstructive Sleep Apnea (OSA) appearing as the primary indexed condition, and to 2 interventions - of which Placebo oral capsule is the first listed.

NCT03426631 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT03426631 about?

NCT03426631 is a clinical study titled "DAW1033B2 in Obstructive Sleep Apnea". Obstructive sleep apnea (OSA) is common and has major health implications but treatment options are limited. OSA patients show a marked reduction in upper airway (UA) dilator muscle activity at sleep onset and this phenomenon leads to increased collapsibility of UA compared to normal subjects. In th...

What is the current status of trial NCT03426631?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 2017-09-15. Estimated completion is 2020-01-20.

What conditions does trial NCT03426631 study?

This clinical trial studies the following conditions: Obstructive Sleep Apnea (OSA).

What interventions are being tested in trial NCT03426631?

The interventions under investigation include: Placebo oral capsule (DRUG), DAW1033B2 oral capsule (DRUG).

Who is sponsoring clinical trial NCT03426631?

This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03426631 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Obstructive Sleep Apnea (OSA)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.